Biocryst Pharmaceuticals Inc Stock Price, News & Analysis

BioCryst Pharmaceuticals (BCRX) has granted restricted stock units (RSUs) to seven newly-hired employees, covering a total of 48,000 shares of common stock. The RSUs were awarded on May 1, 2025 as employment inducements and comply with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years in equal annual installments, beginning one year from the grant date, contingent on continued employment. These grants are governed by BioCryst's Inducement Equity Incentive Plan and individual RSU agreements.

BioCryst Pharmaceuticals (BCRX) has appointed Steve Frank, chairman of global healthcare investment banking at J.P. Morgan, to its board of directors. Frank brings extensive healthcare investment banking experience, having previously served as global group head of worldwide healthcare investment banking at Bear Stearns. He has a notable background in institutional investing, having built State Farm's multi-billion-dollar life science equity portfolio in the 1980s and early 1990s.

The company highlighted its strong position with a commercial product approaching $1 billion in peak sales, a robust cash position independent of capital markets, and a pipeline of potential best-in-class medicines in development. Frank currently serves on Precigen's board and holds a CFA designation, along with degrees from Illinois State University and the University of Chicago.

BioCryst Pharmaceuticals (Nasdaq: BCRX) has announced its participation in three major investor conferences in May 2025:

• Citizens Life Sciences Conference in New York - May 8, 2025, at 9:00 a.m. ET
• Bank of America 2025 Health Care Conference in Las Vegas - May 14, 2025, at 1:40 p.m. ET
• RBC Capital Markets Global Healthcare Conference in New York - May 21, 2025, at 3:05 p.m. ET

Investors and interested parties can access live audio webcasts and replay recordings of these presentations through the Investors & Media section on BioCryst's website at biocryst.com.

BioCryst Pharmaceuticals (Nasdaq: BCRX) has announced it will release its first quarter 2025 financial results on Monday, May 5, 2025. The company will host a conference call and webcast at 8:30 a.m. ET on the same day, featuring management discussion of financial results and a corporate update.

Interested parties can access the live call by dialing 1-844-481-2942 (domestic) or 1-412-317-1866 (international). A live webcast and replay will be available in the investors section at www.biocryst.com.

BioCryst Pharmaceuticals (BCRX) has granted restricted stock units (RSUs) to 10 newly-hired employees as employment inducements. The grants, approved by the compensation committee, cover a total of 65,500 shares of BioCryst common stock and were issued on April 1, 2025.

The RSUs are structured to vest in four equal annual installments, with the first vesting occurring on the one-year anniversary of the grant date. Vesting is contingent upon continued employment with BioCryst. These equity awards were granted under BioCryst's Inducement Equity Incentive Plan and comply with Nasdaq Listing Rule 5635(c)(4).

BioCryst Pharmaceuticals (Nasdaq: BCRX) has announced its upcoming participation in the 24th Annual Needham Virtual Healthcare Conference. The presentation is scheduled for Wednesday, April 9, 2025, at 9:30 a.m. ET.

Investors and interested parties can access both the live audio webcast and a replay of the presentation through the Investors & Media section on BioCryst's official website at http://www.biocryst.com.

BioCryst Pharmaceuticals (BCRX) has announced the granting of restricted stock units (RSUs) to seven newly-hired employees. The compensation committee approved RSUs covering 65,900 shares of BioCryst common stock, granted on March 3, 2025. These inducement grants, issued under Nasdaq Listing Rule 5635(c)(4), will vest over four equal annual installments starting from the one-year anniversary of the grant date. The vesting is contingent upon continued employment with the company. The RSUs are governed by BioCryst's Inducement Equity Incentive Plan and respective RSU agreements.

BioCryst Pharmaceuticals (BCRX) reported strong Q4 and full year 2024 results, with ORLADEYO net revenue reaching $124.2M in Q4 (+36.6% y-o-y) and $437.7M for FY 2024 (+34.3% y-o-y). The company increased its FY 2025 ORLADEYO revenue guidance to $535-550M.

The company achieved a non-GAAP operating profit of $62.9M in 2024 (excluding stock-based compensation) and expects to approach positive EPS and cash flow in 2H 2025. GAAP operating loss for 2024 was $2.5M, with Q4 net loss at $26.8M ($0.13 per share).

Key pipeline developments include plans to expand ORLADEYO label to children aged 2-11, with NDA submission planned this year. Initial clinical data from BCX17725 for Netherton syndrome and avoralstat for diabetic macular edema are expected by year-end. Cash position stood at $342.8M as of December 31, 2024.

BioCryst Pharmaceuticals (BCRX) announced positive interim results from the APeX-P trial evaluating ORLADEYO® in pediatric HAE patients aged 2 to <12 years. The trial, the largest evaluating prophylactic HAE therapy in this age group, demonstrated that the oral granule formulation was safe and well-tolerated.

Key findings show that after one month of ORLADEYO treatment, median monthly attack rates dropped from 0.96 to 0, maintaining this level through month 12. The mean monthly attack rate decreased from 1.5 to 0.3 attacks at month 12.

Additional real-world evidence presented showed statistically significant HAE attack rate reductions in patients with C1-INH deficiency and normal C1-INH levels. Patients experiencing ≥5 baseline attacks/month showed the largest reductions, with 6.20 fewer attacks/month at 12 months. The company plans to submit a New Drug Application to the FDA this year.